insulin drugs glp 1 receptor agonist market GLP-1 Agonists Size, Share, Growth Insights 2032 GLP-1 Receptor Agonist Market Growth

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

In an investigative report in partnership with KFF Health News, NBC News Anne Thompson reports on the growing cases of overdoses involving GLP-1 weight loss drugs.

Glucagon-like peptide-1 (GLP-1) is one of the incretins that regulate glucose metabolism

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)